
GFRAL RECEPTOR INHIBITOR FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

	Priority Number n. 102023000006387_31.03.2023	Abstra
 KEYWORDS AMYOTROPHIC LATERAL SCLEROSIS CACHEXIA 	Patent Type Patent for invention.	(%) 20 u u u u u u u u u u u u u u u u u u u
SHORT HAIRPIN RNA	Ownership Sapienza University of Rome 100%	-30 VIII IX TO XI XII XIII XIV XV XVI XVII XVII XIX Week Weight
GDF15	Inventors Stefano Garofalo, Cristina Limatola, Germana Cocozza	
AREA PHARMACEUTICAL	Industrial & Commercial Reference Pharmaceutical. Pharmaceutical industries involved in the development and marketing of medicines for hospital use.	injected with GFRAL AAV silencing shRNA (sh group) or empty vector (sc group) at 10 weeks of age - T0. A significant increase in food intake was reported in subjects receiving GFRAL silencing (sh group), from week XIV to week XIX. Treatment SH VS SC *p<0.05.
CONTACTS	Time to Market	20 15 10
 PHONE NUMBERS +39.06.49910888 +39.06.49910855 EMAIL u_brevetti@uniroma1.it 	TRL 4 – technology validated in labAvailabilityAssignment, exclusive or non-exclusivelicense, research, development,experimentation, collaboration and start-up	Fig. 2 Representative graph of body weight in hSOD1G93A mice and non-transgenic mice injected with GFRAL AAV silencing shRNA (sh group) or empty vector (sc group) at 10 weeks of age - T0. A significant increase in body weight was reported in subjects receiving GFRAL silencing (sh group), from week XIV to week XIX. Treatment SH VS SC *p<0.05.

act

yotrophic lateral sclerosis (ALS), loss is an important clinical feature patients at the time of diagnosis. nvention consists in demonstrating volvement of Growth differentiation 15(GDF15) in the metabolic gulation that occurs during ALS ession. GDF15, by acting on its tor GFRAL, causes anorexia and loss in several pathologies. It is sed to administer artificial short RNA molecules capable of ng the GFRAL gene, to counteract loss by acting on GDF15 ing, thus improving the symptoms ality of life of ALS patients.





ARTEM UFFICIO VALORIZZAZIONE E TRASFERIMENTO TECNOLOGICO SETTORE BREVETTI E LICENSING

http://uniroma1.it/ricerca/brevetti

GFRAL RECEPTOR INHIBITOR FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

Technical Description

The patent relates to a GFRAL receptor inhibitor for the treatment of amyotrophic lateral sclerosis (ALS), in particular for the treatment of cachexia and/or to reduce weight loss in ALS patients. The inhibitor is a polynucleotide short hairpin RNA (shRNA). An inhibitor is an agent able to decrease or inhibit the expression of the GFRAL receptor gene. This polynucleotide is able to bind, at least partially, the gene coding for GFRAL and inhibiting its expression, or coding for a molecule capable of binding to the GFRAL gene inhibiting its expression.

Technologies & Advantages

With prevalence of 56%-62% in ALS patients, weight loss is defined as an important and independent prognostic factor. In addition, several studies have reported that the progression of the disease is directly proportional with weight loss or with a low body mass index (BMI), at the time of diagnosis. By implementing specific dietary programs, including various highcalorie fat or sugar diets, ALS patients shown slower disease have progression and better quality of life. This observation focused attention on the influence of the ALS patient's metabolic condition on disease progression. The GDF15 cytokine receptor polynucleotide inhibitor. GFRAL, aims to improve weight loss and cachexia in SLA patients.

Applications

1. A GFRAL receptor inhibitor for use in the treatment of amyotrophic lateral sclerosis (ALS).

2. A GFRAL receptor inhibitor for use in the treatment of ALS-associated cachexia and/or to block and/or reduce weight loss and/or to increase appetite in a person with ALS.

3. The inhibitor for use according to claim 1 or 2 in which the inhibitor blocks, prevents and/or decreases the interaction between GFRAL and GDF15, or blocks, silences and/or decreases the expression of the coding gene for the GFRAL receptor.

4. The inhibitor for use in any of the previous applications where ALS is a sporadic form (sSLA) or a familial genetic form (fsla).

CONTACTS

PHONE NUMBERS
 +39.06.49910888
 +39.06.49910855

EMAILu brevetti@uniroma1.it

SAPIENZA UNIVERSITÀ DI ROMA